Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas
- PMID: 38700610
- DOI: 10.1007/s11060-024-04656-9
Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas
Abstract
Purpose: There is lack of comprehensive analysis evaluating the impact of clinical, molecular, imaging, and surgical data on survival of patients with gliomatosis cerebri (GC). This study aimed to investigate prognostic factors of GC in adult-type diffuse glioma patients.
Methods: Retrospective chart and imaging review was performed in 99 GC patients from adult-type diffuse glioma (among 1,211 patients; 6 oligodendroglioma, 16 IDH-mutant astrocytoma, and 77 IDH-wildtype glioblastoma) from a single institution between 2005 and 2021. Predictors of overall survival (OS) of entire patients and IDH-wildtype glioblastoma patients were determined.
Results: The median OS was 16.7 months (95% confidence interval [CI] 14.2-22.2) in entire patients and 14.3 months (95% CI 12.2-61.9) in IDH-wildtype glioblastoma patients. In entire patients, KPS (hazard ratio [HR] = 0.98, P = 0.004), no 1p/19q codeletion (HR = 10.75, P = 0.019), MGMTp methylation (HR = 0.54, P = 0.028), and hemorrhage (HR = 3.45, P = 0.001) were independent prognostic factors on multivariable analysis. In IDH-wildtype glioblastoma patients, KPS (HR = 2.24, P = 0.075) was the only independent prognostic factor on multivariable analysis. In subgroup of IDH-wildtype glioblastoma with CE tumors, total resection of CE tumor did not remain as a significant prognostic factor (HR = 1.13, P = 0.685).
Conclusions: The prognosis of GC patients is determined by its underlying molecular type and patient performance status. Compared with diffuse glioma without GC, aggressive surgery of CE tumor in GC patients does not improve survival.
Keywords: Glioma; Gliomatosis cerebri; Magnetic resonance imaging; Survival; World Health Organization.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.Eur Radiol. 2024 Feb;34(2):1376-1387. doi: 10.1007/s00330-023-10125-0. Epub 2023 Aug 23. Eur Radiol. 2024. PMID: 37608093
-
Revisiting gliomatosis cerebri in adult-type diffuse gliomas: a comprehensive imaging, genomic and clinical analysis.Acta Neuropathol Commun. 2024 Aug 10;12(1):128. doi: 10.1186/s40478-024-01832-w. Acta Neuropathol Commun. 2024. PMID: 39127694 Free PMC article.
-
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2. Acta Neuropathol Commun. 2020. PMID: 33228806 Free PMC article.
-
Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Pathologe. 2019. PMID: 31025086 Review. English.
-
The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.Neurosurg Focus. 2019 Dec 1;47(6):E13. doi: 10.3171/2019.9.FOCUS19660. Neurosurg Focus. 2019. PMID: 31786548
Cited by
-
Revisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.Eur Radiol. 2025 Jul 9. doi: 10.1007/s00330-025-11768-x. Online ahead of print. Eur Radiol. 2025. PMID: 40628985
-
Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.J Neurooncol. 2024 Sep;169(3):531-541. doi: 10.1007/s11060-024-04737-9. Epub 2024 Aug 8. J Neurooncol. 2024. PMID: 39115615
-
A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging.Korean J Radiol. 2025 Mar;26(3):246-268. doi: 10.3348/kjr.2024.0982. Korean J Radiol. 2025. PMID: 39999966 Free PMC article. Review.
References
-
- Nevin S (1938) Gliomatosis cerebri. Brain 61:170–191. https://doi.org/10.1093/brain/61.2.170 - DOI
-
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4 - DOI - PubMed - PMC
-
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 - DOI - PubMed
-
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106 - DOI - PubMed - PMC
-
- Ranjan S, Warren KE (2017) Gliomatosis Cerebri: Current Understanding and Controversies. Front Oncol 7:165. https://doi.org/10.3389/fonc.2017.00165 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous